| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802941801047 | 294180104 | CINTEROL F.C.TAB 1MG/TAB BTx30 (σε PVC/PE/PVDC-Alu Blister) | 2.25 | 2.36 | 3.25 |
| 05/2018 | 2802941802044 | 294180204 | CINTEROL F.C.TAB 2MG/TAB BTx30 (σε PVC/PE/PVDC-Alu Blister) | 4.19 | 4.40 | 06.06 |
For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
Both tolterodine and its active metabolite, 5-hydroxymethyltolterodine, act as competitive antagonists at muscarinic receptors. This antagonism results in inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder.
1.9-3.7 hours
Following administration of a 5-mg oral dose of 14C-tolterodine solution to healthy volunteers, 77% of radioactivity was recovered in urine and 17% was recovered in feces in 7 days.
* 113 ± 26.7 L